Advanced Skin Cancers Coverage from Every Angle
Editor:
Soo Park, MD
Advertisement
Advertisement

Videos

Pavlina Spiliopoulou, MD, PhD, on Locally Advanced or Metastatic Melanoma: First-Line mRNA-4359 Plus Pembrolizumab

Soo Park, MD, and Vishal Patel, MD, FAAD, FACMS, on Multidisciplinary Care in Advanced Skin Cancers

Carrie R. Daniel-MacDougall, PhD, MPH: Can a Dietary Intervention Affect Immunotherapy Response in Patients With Melanoma?

Neil Gross, MD, FACS, on Neoadjuvant Immunotherapy With Response-Adapted Treatment vs Standard of Care for Resectable Stage III/IV CSCC

Jessica Geiger, MD, on an Active Trial for Immunocompromised Patients With Advanced Skin Cancer

Georgina V. Long, MD, PhD, on Advanced Melanoma: RELATIVITY-098 in Completely Resected Disease

Janice M. Mehnert, MD, on Novel Quadruplet in Unresectable Advanced Melanoma

Ahmad Tarhini, MD, PhD, on High-Risk Resectable Melanoma: Neoadjuvant Therapies

Michael B. Atkins, MD, FASCO, on the Final Clinical Results From DREAMseq

Danny Rischin, MD, on High-Risk CSCC: Adjuvant Therapy

A New Global Hub: Introducing the Merkel Cell Carcinoma Collaborative (MC3) Institute

Carlo M. Contreras, MD, FACS, on Novel Therapies for Skin Cancers: A Surgical Perspective

Mehran Yusuf, MD, on Treating Merkel Cell Carcinoma: A Radiation Oncology Perspective

Gino K. In, MD, MPH, on Non-UV Melanomas: Emerging Role of Intratumoral Immunotherapy

Mehran Yusuf, MD, on Treating Locally Advanced BCC and SCC: The Role of Radiotherapy

Theresa Medina, MD, on Immunotherapies for Cutaneous Squamous Cell Carcinoma

Kelly Olino, MD, FACS: A Surgical Perspective on Treating Advanced or Metastatic Melanoma

Jessica Donigan, MD, on Surgical Management of High-Risk Non-Melanoma Skin Cancers

Axel Hauschild, MD, on Clinical Implications of Using Neoadjuvant Daromun in Locally Advanced Melanoma

Christian U. Blank, MD, PhD, on Clinical Implications of New Findings on Neoadjuvant Nivolumab Plus Ipilimumab in Melanoma

Douglas B. Johnson, MD, MSCI, on Updates on the Treatment Landscape in Cutaneous Melanoma

Sophia McKinley, MD, EdM, on the Role of Adjuvant Immunotherapy for High-Risk Cutaneous Melanoma

Jenny H. Chang, MD, on Neoadjuvant Immunotherapy for Merkel Cell Carcinoma

Tina J. Hieken, MD, on Treatment Advances in High-Risk Regionally Advanced Melanoma: Clinical Implications

Soo Park, MD, on How Immune Checkpoint Inhibitors Are Changing the Treatment Landscape in Cutaneous Squamous Cell Carcinoma

Neil Gross, MD, on Emerging Treatment Spectrum in Advanced Cutaneous Squamous Cell Cancer

Nikhil Khushalani, MD, on an Update on the Treatment Landscape in Non-Melanoma Skin Cancers

Michael K.K. Wong, PhD, MD, on Early Results on Navtemadlin, a Novel MDM2 Inhibitor, for Merkel Cell Carcinoma

Neil D. Gross, MD, on Clinical Implications of Recent Findings on Cemiplimab in Cutaneous Squamous Cell Carcinoma

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Study Results on Retifanlimab

Alexander C. J. van Akkooi, MD, PhD, on Domatinostat Plus Avelumab for Merkel Cell Carcinoma

Shailender Bhatia, MD, on Pembrolizumab in Front-Line Treatment of Merkel Cell Carcinoma

Francis P. Worden, MD, on Vismodegib: Organ Preservation for Orbital/Periocular Basal Cell Carcinoma

Danny Rischin, MD, on Cutaneous Squamous Cell Carcinoma: Follow-up Data on Cemiplimab

Nikolaos Andreatos, MD, on Adverse Events Following Radiotherapy and Immunotherapy in Patients With Melanoma and Merkel Cell Carcinoma

Michael K.K. Wong, MD, PhD, on KRT-232: First-in-Class Agent for Merkel Cell Carcinoma

Steven M. Horwitz, MD, on PTCL and CTCL: Trial Results on Cerdulatinib, a Dual SYK/JAK Inhibitor

Karl D. Lewis, MD, on Selecting Patients for Treatment With Cemiplimab-rwlc

Theresa M. Medina, MD, on Basal Cell Carcinoma and Immunotherapy

Karl D. Lewis, MD, on the Role of Adjuvant Immunotherapy in NMSC

Theresa M. Medina, MD, on Treating Cutaneous Squamous Cell Carcinoma With Cemiplimab-rwlc

Karl D. Lewis, MD, on Drug Therapy: Expanding Treatment Options

Eve Maubec, MD, PhD, on Cutaneous Squamous Cell Carcinoma: Update on Trials

Chrysalyne Schmults, MD, on Basal Cell Carcinoma: Treatment Research Update

Chrysalyne Schmults, MD, on Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma: Treatment Pipeline

Kim A. Margolin, MD, on the Emerging Role of Medical Oncologists in Treating Non-Melanoma Skin Cancers

Eric Roeland, MD, on Prophylactic Strategies for Highly Emetogenic Chemotherapy

Charles von Gunten, MD, PhD, on Opioids for Managing Cancer Pain

Steven M. Horwitz, MD, on SYK/JAK Inhibitor Treatment for T-Cell Lymphomas

Karl Lewis, MD, on a Phase II Study of Cemiplimab for Basal Cell Carcinoma

Chrysalyne D. Schmults, MD, MSCE, on Squamous Cell Carcinoma: Treatment/Costs Study Findings

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Jeremy Warner, MD, on Patient Navigation: The Proactive Approach

Emily S. Ruiz, MD, MPH, on Squamous Cell Carcinoma: Expert Perspective

Danny Rischin, MD, on Cemiplimab for Metastatic Squamous Cell Carcinoma

Chrysalyne D. Schmults, MD, MSCE, and Squamous Cell Carcinoma: Risk of Recurrence

The JNCCN Spotlight

Copyright © 2026 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.